Simplifying CAR T-Cell Manufacturing for R/R B-Cell Non-Hodgkin’s Lymphoma

Video

Manali Kamdar, MD, MBBS, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell non-Hodgkin’s lymphoma.

Manali Kamdar, MD, MBBS, assistant professor of medicine and clinical director of lymphoma services at the University of Colorado Hospital, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor (CAR) T-cell product in adults with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma.


According to Kamdar, genetically engineered CAR T cells have previously exhibited promising results in regard to efficacy against chemotherapy refractory CD19 expressing B-cell malignancies.


During her presentation at the AACR Annual Meeting 2022, Kamdar further explained how the expected timeline from manufacturing to delivery of anti-CD19 CAR T-cell products could be simplified from 3-4 weeks to 2 weeks. By shortening the process, patients with R/R B-cell non-Hodgkin’s lymphoma could have the potential of decreasing the amount of interim therapy and potential morbidity.


Transcription:

0:08 | Genetically engineered CAR T-cell therapies have exhibited distinct efficacy against chemotherapy refractory CD19 expressing B-cell non Hodgkin lymphomas. Our phase 1 clinical trial tests a novel anti-CD19 CAR T-cell product in adults with relapsed/refractory large B-cell lymphoma. It is also important to underscore that the existing CAR T-cell therapy manufacturing takes about 3 to 4 weeks and we typically have to outsource that to the companies that have the approval for the CAR T constructs.


0:48 | In order to simplify the process of CAR T-cell manufacturing, the CliniMax prodigy by Miltenyi was used in this phase 1 clinical trial. The prodigy is basically a self contained, closed, largely automated device that obviates the need for human involvement in numerous steps, thus reducing human resource utilization and the risk of cell contamination.


1:11 | T​​he study investigated a CD19 directed CAR T-cell product that was produced on site by GBF using the prodigy. The idea was that the expected timeline from manufacturing to delivery could be shortened to as less as 2 weeks or even under, thus hopefully decreasing the amount of interim therapy as well as potential morbidity.



Recent Videos
Solly Chedid, MD, and Jamie Koprivnikar, MD
Solly Chedid, MD, and Jamie Koprivnikar, MD
Related Content